Atea Pharmaceuticals Business Summary

Atea Pharmaceuticals, Inc. (AVIR) is a late-stage clinical biopharmaceutical company that operates on a research-driven business model, currently generating zero product revenue as it focuses on the discovery and development of oral antiviral therapeutics. The company’s primary business segments are centered on its proprietary nucleos(t)ide prodrug platform, with its lead development pillar being a Phase 3 program for Hepatitis C (HCV) evaluating a fixed-dose combination of bemnifosbuvir and ruzasvir. Atea is also expanding into Hepatitis E (HEV) with its candidate AT-587, which is slated for Phase 1 trials in mid-2026, and maintains a legacy interest in COVID-19 therapeutics. In the competitive landscape, Atea primarily contends with established pharmaceutical giants like Gilead Sciences and AbbVie in the HCV market, as well as clinical-stage peers such as Trevi Therapeutics and Palvella Therapeutics. The company distinguishes itself by targeting high-risk and immunocompromised populations with oral, pan-genotypic treatments designed to overcome the limitations of current standard-of-care regimens. Leadership is spearheaded by Founder, Chairman, and CEO Jean-Pierre Sommadossi, PhD, a veteran entrepreneur who previously founded Idenix Pharmaceuticals (acquired by Merck) and co-founded Novirio Pharmaceuticals (now part of Gilead). The executive team includes Andrea Corcoran as CFO and EVP of Legal, Dr. Janet Hammond as Chief Development Officer, and Dr. Arantxa Horga as Chief Medical Officer, all of whom bring extensive pedigrees from major firms like Roche, Bristol Myers Squibb, and Merck. The company’s Board of Directors features notable figures such as former U.S. Surgeon General Jerome Adams and industry veterans like Franklin Berger and Barbara Duncan. Atea is backed by a strong base of institutional investors, including Bain Capital Life Sciences, RA Capital Management, and Adage Capital Management, maintaining a robust cash runway of approximately $301.8 million as of early 2026 to fund operations through 2027.